Table 2.
Changes from baseline to week 100 in health‐related quality of life measuresa
| Placebo to ustekinumab 45 mgb | Ustekinumab | |||
|---|---|---|---|---|
| 45 mg | 90 mg | Combined | ||
| Patients randomized, no. | 189 | 205 | 204 | 409 |
| Change from baseline to week 100 | ||||
| SF‐36 PCS score | 4.8 (0.0, 12.7) | 5.1 (0.0, 13.7) | 6.4 (0.0, 14.2) | 5.3 (0.0, 14.1) |
| SF‐36 MCS score | 3.3 (0.0, 11.6) | 3.0 (−1.0, 9.3) | 3.7 (−0.6, 10.7) | 3.2 (−0.8, 9.9) |
| DLQI score | −6.0 (−11.0, −1.0) | −5.0 (−11.5, −1.0) | −6.0 (−11.0, −2.0) | −5.0 (−11.0, −2.0) |
a
Values are the median (interquartile range) unless indicated otherwise. SF‐36 = Short Form 36 health survey; PCS = physical component summary; MCS = mental component summary; DLQI = Dermatology Life Quality Index.
b
Patients in the placebo group who did not receive ustekinumab were excluded.